Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Bai, Xiaoming ^a   Wang, Jie ^b   Guo, Yan ^a   Pan, Jinshun ^a   Yang, Qinyi ^a   Zhang, Min ^a   Li, Hai ^a   Zhang, Li ^a   Ma, Juan ^a   Shi, Feng ^a   Shu, Wei ^a   Wang, Yipin ^a   Leng, Jing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E2; PROTEIN KINASE C;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD29; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; PROTEIN KINASE C; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; SIGNAL TRANSDUCTION;

EID: 84923349232     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06538     Document Type: Article

References (60)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin. 64, 9-29 (2014).
2. El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142, 1264-1273 e1 (2012).
3. Cervello, M. et al. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3, 236-260 (2012).
4. Oshima, H. & Oshima, M. The role of PGE2-Associated inflammatory responses in gastric cancer development. Semin Immunopathol. 35, 139-150 (2012).
5. Li, Z. et al. PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene 32, 1408-1415 (2012).
6. Karavitis, J. et al. Regulation of COX2 expression in mouse mammary tumor cells controls bonemetastasis and PGE2-induction of regulatory T cell migration. PLoS One 7, e46342 (2012).
7. Krysan, K. et al. Prostaglandin E2 activates mitogen-Activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 65, 6275-6281 (2005).
8. Leng, J. et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through AKT activation: evidence for AKT inhibition in celecoxib-induced apoptosis. Hepatology 38, 756-768 (2003).
9. Bai, X. M. et al. Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, migration and invasion in hepatocellular carcinoma cells. Oncol Rep. 21, 129-136 (2009).
10. Mayoral, R. et al. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 26, 753-761 (2005).
11. Wu, T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treatment Reviews 32, 28-44 (2006).
12. Schuppan, D. & Ocker, M. Integrin-mediated control of cell growth. Hepatology 38, 289-291 (2003).
13. Yao, E. S. et al. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 67, 659-664 (2007).
14. Nikkola, J. et al. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res. 14, 29-37 (2004).
15. Muller-Klingspor, V. et al. Prognostic value of beta1-integrin (5CD29) in serous adenocarcinomas of the ovary. Anticancer Res. 21, 2185-2188 (2001).
16. Seales, E. C. et al. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. 65, 4645-4652 (2005).
17. Carloni, V. et al. The integrin, alpha6beta1, is necessary for thematrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells. Hepatology 34, 42-49 (2001).
18. Zhang, H. et al. Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-Activated protein kinase dependent pathway. Cancer 95, 896-906 (2002).
19. Fujimoto, A. et al. Identification of cell surface antigen expression in canine hepatocellular carcinoma cell lines. J Vet Med Sci. 75, 831-835 (2013).
20. Lai, K. K. et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten nullmousemodels. PLoS Genet 7, e1002147 (2011).
21. Boie, Y. et al.Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 340, 227-241 (1997).
22. Park, S. J. et al. The forkhead transcription factor Foxc2 promotes osteoblastogenesis via up-regulation of integrin beta1 expression. Bone 49, 428-438 (2011).
23. Abrahao, A. C. et al. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol. 46, 880-887 (2010).
24. Hussain, T., Gupta, S. & Mukhtar, H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 191, 125-135 (2003).
25. Zhao, Q. T. et al. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-Associated angiogenesis. Life Sci. 80, 484-492 (2007).
26. Cary, L. A. & Guan, J. L. Focal adhesion kinase in integrin-mediated signaling. Front Biosci. 4, D102-113 (1999).
27. Missan, D. S.&DiPersio, M. Integrin control of tumor invasion. Crit Rev Eukaryot Gene Expr. 22, 309-324 (2012).
28. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 5, 662-668 (1999).
29. Ozaki, I. et al. Differential expression of laminin receptors in human hepatocellular carcinoma. Gut 43, 837-842 (1998).
30. Pierro, E. et al. In vitro regulation of beta1 and beta3 integrin subunits in endometrial epithelial cells from normal endometrium. Am J Reprod Immunol. 49, 373-376 (2003).
31. Liu, J. F. et al. Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer. 9, 43-56 (2010).
32. Kajimoto, M. et al. Enhancement of activated beta1-integrin expression by prostaglandin E2 via EP receptors in isolated human coronary arterial endothelial cells: implication for the treatment of Kawasaki disease. Inflamm Res. 58, 224-228 (2009).
33. Yazawa, K. et al. Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin. Cancer Sci. 96, 93-99 (2005).
34. Sugimoto, Y. & Narumiya, S. Prostaglandin E receptors. J Biol Chem. 282, 11613-11617 (2007).
35. Tang, C. H., Yang, R. S. & Fu, W. M. Prostaglandin E2 stimulates fibronectin expression through EP1 receptor, phospholipase C, protein kinase Calpha, and c-Src pathway in primary cultured rat osteoblasts. J Biol Chem. 280, 22907-22916 (2005).
36. Bai, X. M. et al. Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sci. 86, 214-223 (2010).
37. Bai, X. et al. Prostaglandin E(2) receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells. Int J Oncol. 42, 1833-1841 (2013).
38. Han, C. &Wu, T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 280, 24053-24063 (2005).
39. Zhang, L. et al. Prostaglandin E2 enhances mitogen-Activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. Mol Cell Biochem. 305, 19-26 (2007).
40. Sun, B. et al. Prostaglandin E2 receptor EP1 phosphorylate CREB and mediates MMP2 expression in human cholangiocarcinoma cells. Mol Cell Biochem. 378, 195-203 (2013).
41. Bosco, R. et al. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem. 11, 185-199 (2011).
42. Rosse, C. et al. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol. 11, 103-112 (2010).
43. Wu, T. T. et al. Overexpression of protein kinase C alpha mRNA in human hepatocellular carcinoma: a potential marker of disease prognosis. Clin Chim Acta. 382, 54-58 (2007).
44. Wu, T. T. et al. Reduction of PKC alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma. J Cell Biochem. 103, 9-20 (2008).
45. Chen, F., Beezhold, K. & Castranova, V. Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol. 27, 183-204 (2008).
46. Sen, R. & Smale, S. T. Selectivity of the NF-{kappa}B response. Cold Spring Harb Perspect Biol. 2, a000257 (2010).
47. Okamoto, T., Sanda, T. & Asamitsu, K. NF-kappa B signaling and carcinogenesis. Curr Pharm Des. 13, 447-462 (2007).
48. Cheng, C. Y. et al. IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells. Br J Pharmacol. 160, 1595-1610 (2010).
49. Falcone, D. et al. Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF-kappaB in lung cancer and in normal pulmonary tissues. Cell Prolif. 46, 172-182 (2013).
50. Sun, Q. et al. Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-kappaB signaling pathway. Tumour Biol. 34, 2995-3002 (2013).
51. Li, W. et al. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol. 3, 238-243 (2010).
52. Li, J. et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NFkappa B induced matrix metalloproteinase 9 expression. PLoS One. 7, e46264 (2012).
53. Melisi, D. & Chiao, P. J. NF-kappa B as a target for cancer therapy. Expert Opin Ther Targets. 11, 133-144 (2007).
54. Li, X. et al. IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. J Biol Chem. 277, 45129-45140 (2002).
55. Phalitakul, S. et al. Vaspin prevents TNF-Alpha-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kappaB and PKCtheta activation in cultured rat vascular smooth muscle cells. Pharmacol Res. 64, 493-500 (2011).
56. Sun, Z. et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 404, 402-407 (2000).
57. Lin, X. et al. Protein kinase C-theta participates in NF-kappaB activation induced by CD3-CD28 costimulation through selective activation of IkappaB kinase beta. Mol Cell Biol. 20, 2933-2940 (2000).
58. Carlsson, P. & Mahlapuu, M. Forkhead transcription factors: key players in development and metabolism. Dev Biol. 250, 1-23 (2002).
59. Kume, T. The Role of FoxC2 Transcription Factor in Tumor Angiogenesis. J Oncol. 2012, 204593 (2012).
60. Yu, Y. H. et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene 32, 431-443 (2013).